US2009192090A1PendingUtilityA1

Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity

57
Assignee: TAKEDA PHARMACEUTICALPriority: Jun 25, 2003Filed: Dec 31, 2008Published: Jul 30, 2009
Est. expiryJun 25, 2023(expired)· nominal 20-yr term from priority
Inventors:Takumi KawabeHidetaka Kobayashi
A61P 43/00A61P 37/08A61P 37/02A61P 31/12A61P 37/00A61P 31/18A61P 29/00C07K 14/4705A61K 38/10A61P 11/06G01N 33/5047G01N 2800/52G01N 33/5008C07K 1/1077A61P 19/02A61K 38/08A61P 19/04
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune disorder or inflammation or viral infection by administering an amount of a G2-checkpoint-abrogating peptide or peptidomimetic sufficient to inhibit the disease.

Claims

exact text as granted — not AI-modified
1 . A method of treating a disease characterized by an immune disorder or viral infection by administering an effective amount of a G2-checkpoint-abrogating peptide or peptidomimetic comprising the structure selected from the group consisting of CBP500 (SEQ ID NO: 124). CBP501 (SEQ ID NO: 80), CBP504 (SEQ ID NO: 127), CBP505 (SEQ ID NO: 128), CBP506 (SEQ ID NO: 129), CBP510 (SEQ ID NO:93), CBP511 (SEQ ID NO:94), CBP512 (SEQ ID NO:95), and CBP603 (SEQ ID NO:89). 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The method of  claim 1 , comprising administering CBP500 (SEQ ID NO: 124). 
     
     
         6 . The method of  claim 1 , comprising administering CBP501 (SEQ ID NO: 80). 
     
     
         7 . The method of  claim 1 , comprising administering CBP504 (SEQ ID NO: 127). 
     
     
         8 . The method of  claim 1 , comprising administering CBP505 (SEQ ID NO: 128). 
     
     
         9 . The method of  claim 1 , comprising administering CBP506 (SEQ ID NO: 129). 
     
     
         10 . The method of  claim 1 , comprising administering CBP510 (SEQ ID NO: 93). 
     
     
         11 . The method of  claim 1 , comprising administering CBP511 (SEQ ID NO: 94). 
     
     
         12 . The method of  claim 1 , comprising administering CBP512 (SEQ ID NO: 95). 
     
     
         13 . The method of  claim 1 , comprising administering CBP603 (SEQ ID NO: 89). 
     
     
         14 . The method of  claim 1 , wherein the disease is characterized by an immune disorder. 
     
     
         15 - 17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the disease is arthritis. 
     
     
         19 . The method of  claim 1 , wherein the disease is auto-immune disease. 
     
     
         20 . The method of  claim 1 , wherein the disease is collagen disease. 
     
     
         21 . The method of  claim 1 , wherein the disease is allergy. 
     
     
         22 . The method of  claim 1 , wherein the disease is asthma. 
     
     
         23 . The method of  claim 1 , wherein the disease is pollinosis. 
     
     
         24 . The method of  claim 1 , wherein the disease is atopy. 
     
     
         25 . The method of  claim 1 , wherein the disease is characterized by a viral infection. 
     
     
         26 . The method of  claim 1 , wherein the disease is characterized by a viral infection and an immune disorder. 
     
     
         27 . (canceled) 
     
     
         28 . The method of  claim 1 , wherein the disease is HIV AIDS. 
     
     
         29 . The method of  claim 1 , wherein the peptide or peptidomimetic treats the disease by inhibiting viral replication. 
     
     
         30 . The method of  claim 30 , wherein the peptide or peptidomimetic inhibits HIV replication. 
     
     
         31 - 40 . (canceled)

Join the waitlist — get patent alerts

Track US2009192090A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.